About Globus Medical, Inc. Class A Common Stock (GMED)
Globus Medical Inc is a medical device company that specializes in the development and commercialization of innovative products for spine surgery. The company focuses on creating solutions that enhance surgical outcomes and improve patient recovery through advanced technologies, including surgical implants, instruments, and robotics. With a robust portfolio, Globus Medical aims to address various spinal conditions and assist healthcare professionals in providing effective treatment options, ultimately striving to elevate the standard of care in spine surgery. Read More
Shares of medical device company Globus Medical (NYSE:GMED)
jumped 5.1% in the morning session after the company reported strong second-quarter financial results that surpassed Wall Street's expectations for both revenue and profit. The medical device company announced second-quarter worldwide net sales of $745.3 million, an 18.4% increase year-over-year, which topped analyst forecasts. Adjusted earnings per share landed at $0.86, comfortably beating the consensus estimate of $0.75. The results were supported by the ongoing integration of its 2023 acquisition of NuVasive, which expanded the company's global reach and product offerings in the spine technology market. Looking forward, Globus Medical reaffirmed its full-year 2025 guidance, projecting revenue around $2.85 billion and adjusted earnings per share of approximately $3.15, signaling confidence in its outlook.
Medical device company Globus Medical (NYSE:GMED) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 18.4% year on year to $745.3 million. The company expects the full year’s revenue to be around $2.85 billion, close to analysts’ estimates. Its non-GAAP profit of $0.86 per share was 14.1% above analysts’ consensus estimates.
AUDUBON, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025.
Globus Medical (GMED) combines strong fundamentals—32% revenue growth, solid profitability, and zero debt—with a technical setup hinting at a potential breakout. A growth stock worth watching.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Globus Medical (GMED) offers strong growth, solid profitability, and fair valuation, making it an ideal GARP strategy pick for investors seeking balanced returns.
Shares of medical device company Globus Medical (NYSE:GMED)
fell 6.6% in the afternoon session after the unexpected resignation of its President and CEO, Daniel Scavilla.
AUDUBON, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced that Keith Pfeil, Executive Vice President, Chief Operating Officer and Chief Financial Officer, has been appointed President and Chief Executive Officer effective July 18, 2025. Daniel Scavilla has resigned as President and Chief Executive Officer effective July 18, 2025, in order to pursue another opportunity. Additionally, Kyle Kline, Senior Vice President of Finance, has been appointed Senior Vice President and Chief Financial Officer.
AUDUBON, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2025 after the market close on Thursday, August 7, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
AUDUBON, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the expanded Excelsius™ navigation capabilities of its next-generation oscillating system, DuraPro™, as the latest addition to the Power Portfolio, designed to advance procedural workflows through safety features and efficiency.
Globus Medical (NYSE:GMED) is a strong growth stock with solid fundamentals and a potential technical breakout, making it a candidate for investors seeking growth opportunities in the healthcare sector.
Globus Medical (NYSE:GMED) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth in the healthcare sector.
NEW YORK CITY, NY / ACCESS Newswire / June 20, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE:GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Shareholders of Globus Medical would probably like to forget the past six months even happened. The stock dropped 28.9% and now trades at $58.14. This was partly due to its softer quarterly results and might have investors contemplating their next move.
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
